BTK and B-cell chronic lymphocytic leukemia: Zent et al. reported a significant correlation between a longer duration of Bruton tyrosine kinase inhibitor (BTKi) therapy and poorer post-vaccination anti-gE concentration in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) and lymphoplasmacytic lymphoma (LPL) [38].